Syntheses and evaluation of glucosyl aryl thiosemicarbazide and glucosyl thiosemicarbazone derivatives as antioxidant and anti-dyslipidemic agents

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 2, 2009, Pages 386-389

  Ghosh, Samir ^a,b   Misra, Anup Kumar ^a,b   Bhatia, Gitika ^b   Khan, M M ^b   Khanna, A K ^b  

^a BOSE INSTITUTE   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Antidyslipidemic; Antioxidant; Cholesterol; Thiosemicarbazide; Thiosemicarbazone

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; CHOLESTEROL; GEMFIBROZIL; OXYGEN RADICAL; PHOSPHOLIPID; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; THIOSEMICARBAZIDE DERIVATIVE; THIOSEMICARBAZONE DERIVATIVE; TRIACYLGLYCEROL; TYLOXAPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; DRUG EVALUATION, PRECLINICAL; DYSLIPIDEMIAS; RATS; SEMICARBAZIDES; THIOSEMICARBAZONES;

EID: 57849088639     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.070     Document Type: Article

References (41)

1. C.D.R.I. communication no. 7592.
2. Director General. World Health Report. WHO: Geneva, 1998.
3. Brown M.S., and Goldstein J.L. Ann. Rev. Biochem. 52 (1983) 223
4. Ross R. Nature 362 (1993) 801
5. Inoue T. Artherosclerosis 160 (2002) 369
6. Badiman J.J., Fuster V., Chesebro J.H., and Badiman L. Circulation 87 (1983) 3
7. Witzum J.L., and Steinberg D. J. Clin. Invest. 88 (1991) 1785
8. Aviram M. Atherosclerosis 98 (1993) 1
9. Bedwell S., Dean R.I., and Jessup W. Biochem. J. 262 (1989) 707
10. Steinberg D., Parthasarthy S., Carew T.E., Khoo J.C., and Witzum J.L. N. Engl. J. Med. 320 (1989) 915
11. Wierzbicki A.S., and Mikhailidis D.P. Curr. Med. Res. Opin. 16 (2000) 139
12. Schaefer J.R., Schweer H., Ikewaki K., Stracke H., Seyberth H.J., Kaffarnik H., Maisch B., and Steinmetz A. Atherosclerosis 144 (1999) 177
13. Ericsson C.G., Nilsson J., Grip L., Svane B., and Hamsten A. Am. J. Cardiol. 80 (1997) 1125
14. Reddy J.K., Azarnoff D.L., and Hignete C.E. Nature 283 (1980) 397
15. Morton R.E., and Greene D. J. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 3041
16. Bruce C., Sharp D.S., and Tall A.R. J. Lipid Res. 39 (1998) 1071
17. Heinemann T., Axtmann G., and Von Bergmann K. Eur. J. Clin. Invest. 23 (1993) 827
18. Parthasarathy S., Steinbert D., and Swiztum J.L. Ann. Rev. Med. 43 (1992) 219
19. Stehouwer C.D.A., Lambert J., Donker A.J.M., and van Hindsbergh V.W.M. Cardiovasc. Res. 43 (1997) 55
20. Asahina Y., Kashiwagi A., and Nishio Y. Diabetes 44 (1995) 520
21. Poyraz M., Sari M., Demirci F., Kosar M., Demirayak S., and Büyükgüngör O. Polyhedron 27 (2008) 2091
22. Karatas F., Koca M., Kara H., and Servi S. Eur. J. Med. Chem. 41 (2006) 664
23. Shih M.-H., and Ke F.-Y. Bioorg. Med. Chem. 12 (2004) 4633
24. Jose Camarasa M., Fernandez-Resa P., Garcia Lopez M.T., De Las Heras F.G., Mendez-Castrillon P.P., and Felix A.S. Synthesis (1984) 509-510
25. 2 using hexane-EtOAc (2:1) as eluant to furnish pure compound 3 (5.1 g, 94%).
26. 2 using hexane-EtOAc (2:1) as eluant to furnish pure compound 4a-k.
27. 2 using hexane-EtOAc (2:1) as eluant to furnish pure compound 5a-e.
28. Schurr P.E., Schultz J.R., and Parkinson T.M. Lipids 7 (1972) 68
29. Deeg R., and Ziegehorn J. Clin. Chem 29 (1983) 1798
30. Batra S., Bhaduri A.P., Joshi B.S., Roy R., Khanna A.K., and Chander R. Bioorg. Med. Chem. 9 (2001) 3093
31. Buccolo G., and David H. Clin. Chem. 19 (1973) 476
32. Zilversmit D.B., Davis A.K., Memphis B.S., and Tenn J.L. Clin. Med. 35 (1985) 831
33. Wing D.R., and Robinson D.F. Biochem. J. 109 (1968) 841
34. Mosinger F.J. Lipid. Res. 6 (1965) 157
35. Lipid lowering activity: Adult male Charles Foster rats (200 ± 225 g) bred in the animal house of the institute were used for the lipid lowering activity. Rats were divided in control, triton induced, triton plus compounds and Gemfibrozil (100 mg/Kg) treated groups containing six rats in each. Hyperlipidemia was developed by administration of Triton WR-1339 (Sigma chemical co., St. Louis, USA) at a dose of 400 mg/Kg body wt. intraperitoneally to animals of all groups except the control. Compounds 4a-k and 5a-e were macerated with gum acacia (0.2% w/v), suspended in water and fed simultaneously with triton at a dose of 100 mg/Kg po to the animals of treated groups. Animals of the control and triton group without treatment with test compounds were given same amount of gum acacia suspension (vehicle). After 18 h of treatment (50 mg/kg b. wt.) 1.0 mL blood was withdrawn from retro-orbital sinus using glass capillary in EDTA coated eppendorf tube (3.0 mg/mL blood). The blood was centrifuged (at 2500 g) at 4 °C for 10 minand the plasma was separated. Plasma was diluted with normal saline (ratio 1:3) and used for analysis of total cholesterol (TC), phospholipids (PL), triglycerides (Tg) by standard procedures.
36. 4 buffer (pH 7.4) to a final volume of 2.5 mL. The above reaction mixtures in the absence or presence of test compounds (100 μg/mL and 200 μg/mL) were incubated at 37 °C for 90 min. The test compounds were also studied for their inhibitory action against microsomal lipid peroxidation in vitro by non-enzymatic inducer. Reference tubes and reagents blanks were also run simultaneously. Malondialdehyde (MDA) contents in both experimental and reference tubes were estimated spectrophotometrically by thiobarbituric acid as mentioned above. Alloprinol, Mannitol and α-tocopherol were used as standard drugs for superoxide, hydroxylations and microsomal lipid peroxidation. All experimental data were analyzed using Student's t-test. Oxidized LDL was compared with the test compounds treated oxidized LDL. The generation of oxygen free radicals were compared in the presence and absence of test compounds. The hyperlipidemic group was compared with control and hyperlipidemic plus drug treated groups P < 0.05 was considered to be significant.
37. Halliwell B., Gutteridge J.M.C., and Arouma O. Anal. Biochem. 165 (1987) 215
38. Schotz M.C., Scanu A., and Page T.H. Am. J. Physiol. 188 (1957) 399
39. Bindoli A., Valente M., and Cavallin L. Pharmacol. Res. Commun. 17 (1985) 831
40. Okhawa H.Q. Anal. Biochem. 95 (1978) 351
41. Batra S., Srivastava S., Singh K., Chander R., Khanna A.K., and Bhaduri A.P. Bioorg. Med. Chem. 8 (2000) 2195